Levodopa—carbidopa intestinal gel in advanced Parkinson’s disease open-label study: Interim results

Levodopa–carbidopa intestinal gel (LCIG) delivered continuously via percutaneous endoscopic gastrojejunostomy (PEG-J) tube has been reported, mainly in small open-label studies, to significantly alleviate motor complications in Parkinson’s disease (PD). A prospective open-label, 54-week, internation...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Fernandez, Hubert H., Vanagunas, Arvydas, Odin, Per, Espay, Alberto J., Hauser, Robert A., Standaert, David G., Chatamra, Krai, Benesh, Janet, Pritchett, Yili, Hass, Steven L., Lenz, Robert A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2013
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3661282/
https://ncbi.nlm.nih.gov/pubmed/23287001
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.parkreldis.2012.11.020
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi